Form 4: United Therapeutics CFO Exercises Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of common stock on October 7, 2024.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised stock options at prices of $120.26 and $117.76.
• He sold shares at a price of $355.54.
• Some option exercises were 'sell-to-cover' transactions, where a portion of the shares obtained from exercising options were sold to cover the exercise cost.
• Following the reported transactions, Edgemond directly owns 5,884 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-existing plan, with no indication of positive or negative implications for the company's performance.

Positives

• The transactions were pre-planned under a Rule 10b5-1 trading plan, suggesting they were not based on insider information.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in the financial industry.
• Companies like Pfizer, Amgen, and Johnson & Johnson also have executives who utilize 10b5-1 trading plans.
• The volume of shares traded by Edgemond is relatively small compared to the overall market capitalization of United Therapeutics, suggesting a limited impact on the stock price.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders, as they are part of a pre-planned trading strategy.

Key Dates